Clinical trials: Bacterial Overgrowth
Liver Cirrhosis, Ascites
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
This investigational trial will be assessing the effect of rifaximin on pathophysiology and haemodynamics in the patient with liver cirrhosis, and addressing the effect of rifaximin on several organs on marker level.
- Trial name
- NCT01769040
- Testing
- Rifaximin
- Where
- Denmark
- Volunteers
- 54 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Evaluations, Diagnostic Self, Antimicrobial
ZnO Nanoparticles Coated Orthodontic Molar Tube
Orthodontic treatment is an elective procedure to improve the patient's dentofacial appearance. The complex design of fixed appliances provides a platform that leads to increased plaque accumulation around orthodontic brackets.
- Conditions
- Evaluations, Diagnostic Self, Antimicrobial, Orthodontic Appliance Complication, Bacterial Overgrowth
- Trial name
- ZnONPs (NCT06089720)
- Testing
- Zinc oxide nanoparticle coated orthodontic molar tubes (experimental), orthodontic molar tubes (control)
- Where
- Iraq
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Baghdad
Hematologic Neoplasms, Gram-Negative Bacterial Infections
Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
This is a prospective, single-arm, observational, exploratory clinical study to evaluate whether the standard fixed dose of ceftazidime-avibactam (CAZ-AVI) achieves sufficient drug exposure (pharmacokinetic/pharmacodynamic, or…
- Conditions
- Hematologic Neoplasms, Gram-Negative Bacterial Infections, Pseudomonas Aeruginosa Infection, Klebsiella Pneumoniae Infections
- Trial name
- CZA-TDM (NCT07703644)
- Testing
- Ceftazidime-avibactam, Therapeutic Drug Monitoring (TDM) and Microbiological Surveillance
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sizhou Feng
Antimicrobial Stewardship Program, Resistance Bacterial
Antimicrobial Stewardship Program Implementation in Brazilian Public Hospitals (PeGASUS)
Antimicrobial resistance is a major global public health challenge, leading to increased morbidity, mortality, and healthcare costs.
- Trial name
- PeGASUS (NCT07514884)
- Testing
- ASP implementation
- Where
- Brazil
- Volunteers
- 54 people
- Sponsor
- Hospital Alemão Oswaldo Cruz
Irritable Bowel Syndrome
Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome
Irritable bowel syndrome (IBS) is a common disease and the pathogenesis of this disease includes central and peripheral mechanisms.
- Trial name
- NCT02565654
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Constipation
Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Patients with constipation often have bloating and abdominal distension. It is unclear if this is related to intestinal bacteria.
- Trial name
- NCT00844831
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Louisville
Bacterial Resistance
Community Epidemiology and Typology of Third-generation Cephalosporins Resistant Enterobacteriaceae in Reunion Island
In its report dated april 2014, World Health Organization confirms antibiotic resistance dissemination in all parts of the world, in hospitals and in community and worries about a possible comeback to a pre-antibiotic era during…
- Trial name
- AB-RUN (NCT03226314)
- Testing
- stool sample
- Where
- Reunion
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de la Réunion
Eravacycline, Pharmacokinetics
Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients
The aim of this study is to evaluate the efficacy of Eravacycline in the treatment of patients with bacterial infection and to assess the pharmacokinetics of Eravacycline and to establish a population pharmacokinetic model of…
- Conditions
- Eravacycline, Pharmacokinetics, Bacteria Infection, Bacterial Resistance to Antimicrobial
- Trial name
- NCT06666998
- Volunteers
- 100 people
- Sponsor
- Sichuan Provincial People's Hospital
Resistance Bacterial, Enterobacteriaceae Infections
Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities
The continuing spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) is among the most important problems in antimicrobial resistance.
- Trial name
- MODERN (NCT03477084)
- Testing
- ESBL-producing enterobacteriaceae carriage
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hepatic Encephalopathy
The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
This is a prospective study designed to examine the role of bacterial overgrowth and delayed intestinal transit and the effect of Rifaximin with hepatic encephalopathy (HE). This study is divided into Phase A and Phase B.
- Trial name
- NCT01846806
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NYU Langone Health
Bacterial Infections
Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance
Assess efficacy of piperacillin/tazobactam in reducing the cases of colonization and infection of bacteria.
- Trial name
- NCT01788449
- Volunteers
- 335 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Urinary Tract Infections, Enterobacteriaceae Infections
Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
This study evaluates the efficacy in achieving clinical cure in non-bacteremic urinary tract infections (UTI) caused by Escherichia coli or Klebsiella pneumoniae producers of extended-spectrum β-lactamases (ESBL) in adult…
- Conditions
- Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria, Carbapenem
- Trial name
- CAPITIS (NCT03891433)
- Testing
- Meropenem, Ertapenem 1000 MG, Piperacillin, Tazobactam 4-0.5G Solution for Injection
- Where
- Colombia
- Volunteers
- 198 people
- Sponsor
- Universidad del Norte
Human Gut Microbiota
Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota
The purpose of this study is to compare and contrast the effects of a prebiotic (Trametes Versicolor), a probiotic (Saccharomyces boulardii) and an antibiotic (amoxicillin) on the gut microbiota of healthy volunteers.
- Trial name
- NCT01414010
- Testing
- Trametes versicolor extract, Saccharomyces boulardii, Amoxicillin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Small Intestinal Bacterial Overgrowth
A Trial of a Multi-Component Nutritional Supplement in Hydrogen-Dominant Small Intestinal Bacterial Overgrowth
The goal of this trial is to evaluate the safety and tolerability of an 8-week, multi-component nutritional supplement (AV1PD1A) in adults with hydrogen-dominant small intestinal bacterial overgrowth (SIBO).
- Trial name
- AV1-SIBO (NCT07215676)
- Testing
- AV1PD1A
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National University of Natural Medicine
Celiac Disease
Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease
Celiac disease is a condition in which the small intestine is damaged by gluten, the storage protein of wheat and similar proteins in barley and rye.
- Trial name
- NCT01137955
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Bacterial Resistance, Methicillin-Sensitive Staphylococcus Aureus Infection
Antistaphylococcal Betalactam and Emergence of Resistance
Antistaphylococcal penicillins are recommanded as first-line agent in methicillin-suceptible Staphylococcus aureus bacteraemia. Several studies in progress are investigating the efficacy and safety of cefazolin compared with…
- Trial name
- CePasR (NCT05939479)
- Where
- France
- Volunteers
- 644 people
- Sponsor
- Central Hospital, Nancy, France
Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease
Efficacy of AEMCOLO (Rifamycin SV MMX) in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO)
Open label interventional randomized pilot study utilizing two dosing regimens of AEMCOLO. The goal of this study is to evaluate effectiveness of a novel antibiotic, AEMCOLO (Rifamycin SV MMX) in the treatment of Small intestinal…
- Conditions
- Small Intestinal Bacterial Overgrowth, Gastrointestinal Disease, Gastrointestinal Infection
- Trial name
- NCT04501380
- Testing
- AEMCOLO (Rifamycin SV MMX)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bradley Connor
Resistant Infection, Antibiotic Resistant Infection
Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria
This study evaluates the impact of rank of Beta lactam antibiotics on emergence of mutlidrug resistant bacteria colonization in intensive care It's retrospective case controle study.
- Conditions
- Resistant Infection, Antibiotic Resistant Infection, Beta Lactam Resistant Bacterial Infection, Bacterial Resistance
- Trial name
- INOR Blact (NCT03752476)
- Testing
- number of Beta lactam class prescription for the same infection
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Cancer
The FOCCUS Study: "Focusing on Cancers Chemotherapys' Untreated Symptoms"
The aim of the study is to identify how often gastrointestinal problems interfere with quality of life as a result of treatment for cancer with chemotherapy.
- Trial name
- FOCCUS (NCT02121626)
- Where
- United Kingdom
- Volunteers
- 248 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Bacterial Resistance to Antimicrobial
Prevalence of Digestive Carriage of Integrons
Bacterial resistance to antimicrobials is an increasing problem. Doctors occasionally face genuine therapeutic dead-ends, when attempting to cure nosocomial infections and, more and more frequently, community-acquired infections.
- Trial name
- APIHA (NCT01985217)
- Where
- France
- Volunteers
- 492 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges